MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.44%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-05-11 | -0.18 | -0.14 | +22.2% |
| 2026-03-23 | -0.13 | -0.14 | -5.2% |
| 2025-11-07 | -0.19 | -0.27 | -42.1% |
| 2025-08-11 | -0.25 | -0.17 | +32.8% |
| 2025-08-08 | -0.25 | Pending | -- |
| 2025-05-09 | -0.18 | -0.16 | +11.1% |
| 2025-03-21 | -0.35 | -0.20 | +43.7% |
| 2024-11-12 | -0.47 | -0.11 | +76.6% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$6.4M | -$6.7M | — | -$6.7M | -0.14 |
| 2025-12-31 | — | -$3.6M | -$3.6M | — | -$4.0M | — |
| 2025-09-30 | — | -$8.9M | -$8.9M | — | -$9.4M | -0.27 |
| 2025-06-30 | — | -$5.3M | -$5.2M | — | -$5.2M | -0.18 |
| 2025-03-31 | — | -$4.5M | -$5.4M | — | -$5.4M | -0.16 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2025-12-22 | LOUIE NGAR YEE | Director | 81,699 | $100.0K |
| 2025-12-22 | CHAOUKI STEVEN M | Director | 40,849 | $50.0K |
| 2025-12-22 | SMITH STAN V | Director | 57,189 | $70.0K |
| 2025-12-05 | SMITH STAN V | Director | 13,740 | $16.4K |
| 2025-11-28 | VITOC VLAD | Chief Executive Officer | 72,000 | $79.8K |
| 2025-11-28 | VITOC VLAD | Chief Executive Officer | 72,000 | $79.8K |
| 2025-11-28 | LUPUT CRISTIAN | Director | 38,145 | $41.8K |
| 2025-11-26 | SMITH STAN V | Director | 15,000 | $15.6K |
| 2025-11-25 | VITOC VLAD | Chief Executive Officer | 10,500 | $10.1K |
| 2025-11-25 | VITOC VLAD | Chief Executive Officer | 10,500 | $10.1K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Solas Capital Management, LLC | 4.3M | $5.5M | 0.1% |
| Alyeska Investment Group, L.p. | 2.5M | $3.2M | 0.0% |
| Vanguard Capital Management LLC | 2.1M | $2.7M | 0.0% |
| 683 Capital Management LLC | 1.1M | $1.4M | 0.0% |
| Centric Wealth Management | 796.7K | $1.0M | 0.0% |
| Cable Car Capital, LP | 648.5K | $830.1K | 0.0% |
| Bleichroeder LP | 500.0K | $640.0K | 0.0% |
| Geode Capital Management, LLC | 360.5K | $461.4K | 0.0% |
| Vanguard Fiduciary Trust Co | 199.3K | $255.1K | 0.0% |
| State Street Corporation | 138.9K | $177.9K | 0.0% |
$43.4M
20.65
0.226
2
1.00
4.71
0.1%
13
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-05-11 | $-0.18 | $-0.14 | +22.2% |
| 2026-03-23 | $-0.13 | $-0.14 | -5.2% |
| 2025-11-07 | $-0.19 | $-0.27 | -42.1% |
| 2025-08-11 | $-0.25 | $-0.17 | +32.8% |
| 2025-08-08 | $-0.25 | Pending | — |
| 2025-05-09 | $-0.18 | $-0.16 | +11.1% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($12.13, 2 analysts) | |||
| 10 | $12.90 | +$108.40 (841%) | 57.1R |
| 50 | $64.50 | +$542.00 (841%) | 57.1R |
| 100 | $129.00 | +$1,084.00 (841%) | 57.1R |
| To Fair Value ($40.50) | |||
| 10 | $12.90 | +$392.10 (3040%) | 206.4R |
| 50 | $64.50 | +$1,960.50 (3040%) | 206.4R |
| 100 | $129.00 | +$3,921.00 (3040%) | 206.4R |
- Elevated short interest (4.71 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| BCX | 0.263 |
| CRVS | 0.263 |
| USAS | 0.260 |
| VOYG | 0.248 |
| AVR | 0.248 |
| Ticker | Correlation |
|---|---|
| BAES.L | -0.148 |
| BFLBY | -0.138 |
| 010950.KS | -0.131 |
| VTGDF | -0.130 |
| NISUY | -0.130 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.